// App-Quantinova.ai

AB0011 (2022) : DNA METHYLATION AS A BIOMARKER OF TOCILIZUMAB RESPONSE IN RHEUMATOID ARTHRITIS PATIENTS

Researchers

Presenter

  • N. Nair

Principal Investigators

  • D. Plant

  • J. Isaacs

  • A. Morgan

  • K. Hyrich

  • A. Barton

  • A. G. Wilson

Medical Centers

  • The University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

  • Newcastle University and Musculoskeletal Directorate, Translational and Clinical Research Institute, Newcastle upon Tyne, United Kingdom

  • University of Leeds, Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, United Kingdom

  • NIHR Leeds BRC, Leeds Teaching Hospitals Teaching Trust, Leeds, United Kingdom

  • NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospital NHS Foundation Trust, Manchester, United Kingdom

  • The University of Manchester, Versus Arthritis Centre for Epidemiology, Manchester Academic Health Sciences Centre, Manchester, United Kingdom

  • University College Dublin School of Biomolecular and Biomedical Science, Dublin, Ireland

Locations

  • United Kingdom

  • Ireland

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • DNA methylation

Drug/Treatment

  • Glucocorticoid

  • Tocilizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • GlaxoSmithKline (GSK)

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved